MA51587A - Conjugués oligomère de sauts d'exons pour la dystrophie musculaire - Google Patents
Conjugués oligomère de sauts d'exons pour la dystrophie musculaireInfo
- Publication number
- MA51587A MA51587A MA051587A MA51587A MA51587A MA 51587 A MA51587 A MA 51587A MA 051587 A MA051587 A MA 051587A MA 51587 A MA51587 A MA 51587A MA 51587 A MA51587 A MA 51587A
- Authority
- MA
- Morocco
- Prior art keywords
- muscle dystrophy
- oligomeric conjugates
- exon
- jumping
- exon jumping
- Prior art date
Links
- 230000009191 jumping Effects 0.000 title 1
- 210000003205 muscle Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436182P | 2016-12-19 | 2016-12-19 | |
| PCT/US2017/066222 WO2018118599A1 (fr) | 2016-12-19 | 2017-12-13 | Conjugués oligomère de sauts d'exons pour la dystrophie musculaire |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA51587A true MA51587A (fr) | 2019-10-23 |
| MA51587B1 MA51587B1 (fr) | 2022-09-30 |
Family
ID=65895706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA51587A MA51587B1 (fr) | 2016-12-19 | 2017-12-13 | Conjugués oligomère de sauts d'exons pour la dystrophie musculaire |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR110389A1 (fr) |
| MA (1) | MA51587B1 (fr) |
-
2017
- 2017-12-13 MA MA51587A patent/MA51587B1/fr unknown
- 2017-12-18 AR ARP170103551A patent/AR110389A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MA51587B1 (fr) | 2022-09-30 |
| AR110389A1 (es) | 2019-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR25C1001I2 (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
| EP3347026A4 (fr) | Modification génétique de macrophages pour l'immunothérapie | |
| EP3353278A4 (fr) | Préparation d'échantillons pour des types d'échantillons compliqués | |
| MA71266A (fr) | Procédés d'intervention précoce pour prévenir ou améliorer la toxicité | |
| IL255125A0 (en) | Evaluation of cas9 molecule/guide rna molecule complexs | |
| EP3423044A4 (fr) | Nanovaccin activant sting pour l'immunothérapie | |
| EP3356612A4 (fr) | Détail facilité pour membranes d'imperméabilisation pré-appliquées | |
| MA46652A (fr) | Polythérapie pour l'inhibition de c3 | |
| EP3334499A4 (fr) | Conjugués bioactifs pour l'administration d'oligonucléotides | |
| EP3341485A4 (fr) | Production améliorée d'immunoglobulines | |
| MA52801A (fr) | Conjugués oligomères à saut d'exon pour dystrophie musculaire | |
| EP3383418A4 (fr) | Peptides slc45a2 pour l'immunothérapie | |
| EP3409108A4 (fr) | Couvre-lit pour lit d'animaux de compagnie | |
| EP3464636A4 (fr) | Extension d'amorce conditionnelle pour la détection de molécule unique | |
| MA45845A (fr) | Traitement d'association pour cancers hématologiques | |
| EP3627918C0 (fr) | Radiorecherche d'extension de couverture pour ec-gsm | |
| MA46048A (fr) | Kit de débutant pour le titrage de l'insuline de base | |
| EP3476478A4 (fr) | Composition pour l'élimination de composés soufrés | |
| EP3397360A4 (fr) | Ensemble de pédale pour machine d'exercice | |
| FR3034840B3 (fr) | Ensemble d'eclairage flexible pour voutes courbees | |
| EP3541379A4 (fr) | Compositions pour le traitement de l'hypertension | |
| EP3443969A4 (fr) | Composition d'amélioration de la fonction cérébrale pour nouveau-nés | |
| EP3633372A4 (fr) | Biomarqueur pour la maladie d'alzheimer | |
| EP3344650A4 (fr) | Aav-epo pour le traitement d'animaux de compagnie | |
| EP3538087A4 (fr) | Réactifs basés sur une oxydo-réduction pour la bioconjugaison d'une méthionine |